



**KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH**  
(A unit of Kovai Medical Center and Hospital Limited)  
Coimbatore, Tamil Nadu

## **Department Of Pharmacology** **New Drug Update**

(New Drugs and Available Drugs with New Formulation)



**Series - 13**  
**August 2020**

### **New drugs approved by FDA**

1. Fostemsavir
2. Remimazolam
3. Adalimumab-fkjp (Biosimilar)
4. Collagenase clostridium histolyticum-aes
5. Decitabine and cedazuridine
6. Oxymetazoline hydrochloride
7. Calcipotriene and betamethasone dipropionate
8. Calcium, magnesium, potassium, and sodium oxybates
9. Budesonide/glycopyrrolate/formoterol fumarate
10. Abametapir
11. Brexucabtagene autoleucel
12. Tafasitamab-cxix

### **New drugs approved by CDSCO**

13. Favipiravir
14. n-alkyl dimethyl benzyl ammonium chloride

**1. Fostemsavir****Date of Approval:** July 2, 2020**Mechanism of action:** Converted into active form temsavir and inhibits gp120-directed attachment of HIV**Indication:** HIV Infection type 1**Dosage Formulation:** Extended-Release Tablets**2. Remimazolam****Date of Approval:** , July 2, 2020**Mechanism of action:** Potentiate the effects of GABAA-receptor (ultrashort acting benzodiazepine)**Indication:** Induction and maintenance of anaesthesia for short procedures**Dosage Formulation:** IV injection**3. Adalimumab-fkjp (Biosimilar)****Date of Approval:** July 6, 2020**Mechanism of action:** Tumor necrosis factor - a blocker**Indication:** Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease, Ulcerative colitis, Plaque psoriasis**Dosage Formulation:** Subcutaneous injection**4. Collagenase clostridium histolyticum-aaes****Date of Approval:** July 6, 2020**Mechanism of action:** Protease enzymes, hydrolyze collagen's triple-helical conformation and lyses collagen deposits**Indication:** Moderate to severe cellulite**Dosage Formulation:** Intralesional injection**5. Decitabine and cedazuridine****Date of Approval:** July 7, 2020**Mechanism of action:** Nucleoside metabolic inhibitor and cytidine deaminase inhibitor**Indication:** Myelodysplastic syndromes**Dosage Formulation:** IV injection**6. Oxymetazoline hydrochloride****Date of Approval:** July 8 , 2020**Mechanism of action:**  $\alpha_2$ -adrenergic receptor agonist**Indication:** Blepharoptosis**Dosage Formulation:** 0.1% Ophthalmic solution

**7. Calcipotriene and betamethasone dipropionate****Date of Approval:** July 20, 2020**Mechanism of action:** Vitamin D analogue, and corticosteroid combination. Reduces redness, thickening, and scaling of the skin**Indication:** Plaque psoriasis**Dosage Formulation:** Cream**8. Calcium, magnesium, potassium, and sodium oxybates****Date of Approval:** July 21, 2020**Mechanism of action:** Hypothesized that action is mediated through GABA<sub>B</sub> actions during sleep at noradrenergic and dopaminergic neurons**Indication:** Narcolepsy**Dosage Formulation:** Oral solution**9. Budesonide/glycopyrrolate/formoterol fumarate****Date of Approval:** July 23, 2020**Mechanism of action:** Combination of corticosteroid, muscarinic antagonist, beta agonist**Indication:** Maintenance therapy in COPD**Dosage Formulation:** Metered dose inhaler**10. Abametapir****Date of Approval:** July 24, 2020**Mechanism of action:** Metalloproteinase inhibitor. Inhibits egg development and survival of lice**Indication:** Head lice infestation**Dosage Formulation:** Lotion**11. Brexucabtagene autoleucel****Date of Approval:** July 24, 2020**Mechanism of action:** First cell based gene therapy. CD19-directed genetically modified autologous T cell immunotherapy**Indication:** Used in combination with lenalidomide for diffuse large B-cell lymphoma**Dosage Formulation:** IV infusion**12. Tafasitamab-cxix****Date of Approval:** July 31, 2020**Mechanism of action:** CD19-directed cytolytic antibody**Indication:** Refractory mantle cell lymphoma**Dosage Formulation:** IV injection

**13. Favipiravir**

**Date of Approval:** July 22, 2020

**Mechanism of action:** Inhibits RNA-dependent RNA polymerase

**Indication:** Mild to moderate COVID 19

**Dosage Formulation:** Film coated tablet

**14. n-alkyl dimethyl benzyl ammonium chloride**

**Date of Approval:** July 31, 2020

**Mechanism of action:** Quaternary ammonium compound with surfactant properties

**Indication:** Antiseptic agent for hands and inanimate object

**Dosage Formulation:** 0.105% spray